Cencora (NYSE: COR) has announced an agreement to acquire American Oncology Network (OTCQX: AONC) in a transaction valued at up to $2.4 billion, expanding the pharmaceutical distribution giant’s presence in community-based cancer care. The deal, announced October 21, 2026, will add a physician-led network of more than 350 oncology providers operating across 21 states to Cencora’s growing healthcare services platform.
The acquisition represents another significant step in Cencora’s strategy to expand beyond traditional pharmaceutical distribution and strengthen its relationships with healthcare providers. By integrating American Oncology Network’s clinical infrastructure and practice management capabilities, Cencora aims to support independent cancer specialists while improving patient access to advanced treatments.
Under the agreement, American Oncology Network is valued at $2.3 billion at closing, with an additional $100 million potentially payable through contingent value rights tied to specified conditions. Cencora already owns approximately 4% of the company and has agreed to acquire the remaining equity interests, subject to a potential ownership rollover by existing shareholders.
If eligible shareholders retain a combined 25% stake, Cencora expects to pay approximately $1.7 billion at closing to increase its ownership to 75%. The transaction remains subject to regulatory approvals, shareholder approval, and customary closing conditions.
Founded in 2018, American Oncology Network provides operational and administrative support to independent oncology practices, allowing physicians to concentrate on patient care. Its services include practice management, technology, and access to integrated healthcare resources designed to help smaller cancer treatment centers compete in an increasingly complex healthcare environment.
For Cencora, the acquisition expands its physician-led oncology management services organization into 12 additional states. The company expects the combination to create opportunities to strengthen cancer treatment delivery, expand practice support capabilities, and improve operational efficiency.
The transaction also highlights the growing importance of community oncology as cancer treatments become increasingly specialized and expensive. Independent oncology practices face mounting challenges involving reimbursement, drug procurement, technology investment, and administrative costs. Larger healthcare organizations are responding by building networks that provide centralized resources while allowing physicians to retain control over clinical decisions.
The expansion comes as biotechnology companies continue developing innovative cancer treatments that could eventually reach patients through community oncology practices. Companies such as Greenwich LifeSciences (NASDAQ: GLSI), which is developing an investigational immunotherapy for breast cancer, and MAIA Biotechnology (NYSE American: MAIA), which is advancing a telomere-targeting cancer treatment, illustrate the broader pipeline of emerging oncology therapies. Neither company is involved in the announced transaction.
For investors, the deal underscores how pharmaceutical distribution companies are seeking additional growth opportunities in specialized healthcare services. Expanding into oncology practice management could provide Cencora with deeper relationships across the cancer treatment market while supporting demand for pharmaceutical products and services.
Cencora expects the acquisition to contribute positively to adjusted diluted earnings per share beginning in the second year following completion. The company also raised its fiscal 2026 adjusted earnings outlook to at least $17.90 per share, reflecting strength in its U.S. Healthcare Solutions business.
The acquisition illustrates a broader shift toward integrated cancer care, where pharmaceutical distribution, clinical services, and healthcare technology increasingly operate within connected networks. As cancer treatments continue evolving, companies capable of supporting both drug delivery and community-based medical practices could play a larger role in shaping the future of oncology care.